Compare AVLN & CRSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | CRSR |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 2020 |
| Metric | AVLN | CRSR |
|---|---|---|
| Price | $33.84 | $13.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 175.5K | ★ 1.3M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.37 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $1,472,480,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.90 |
| P/E Ratio | ★ N/A | $72.53 |
| Revenue Growth | N/A | ★ 11.86 |
| 52 Week Low | $24.90 | $4.48 |
| 52 Week High | $40.17 | $14.98 |
| Indicator | AVLN | CRSR |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 55.68 |
| Support Level | $34.22 | $8.18 |
| Resistance Level | $40.08 | $13.10 |
| Average True Range (ATR) | 1.96 | 0.47 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 9.89 | 73.47 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).